<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01259193</url>
  </required_header>
  <id_info>
    <org_study_id>SRFB-021</org_study_id>
    <secondary_id>LCI-10-10-20</secondary_id>
    <nct_id>NCT01259193</nct_id>
  </id_info>
  <brief_title>Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC</brief_title>
  <official_title>Phase II Study of Sorafenib and Zoledronic Acid in Advanced HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sorafenib ,an oral multikinase inhibitor targeting several tyrosine-kinase receptors with
      antiangiogenesis and antiproliferation of HCC, is the first approved target therapy for HCC.

      Zoledronic acid is used for treatment of bone metastasis of diverse malignant cancer.
      Emerging data suggest that zoledronic acid may also exhibit anticancer properties.

      The objectives of the study is to evaluate the safety of Sorafenib combined with Zoledronic
      Acid and to evaluate overall survival and time to progression.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>numbers of adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>to evaluate the toxicity of sorafenib in combination with zoledronic acid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS), time to progression (TTP)</measure>
    <time_frame>1 year</time_frame>
    <description>to evaluate the efficacy of sorafenib in combination with zoledronic acid</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib and Zoledronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib and Zoledronic Acid</intervention_name>
    <description>Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year</description>
    <arm_group_label>Sorafenib and Zoledronic Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Hepatocellular carcinoma confirmed with pathology or identified with radiological
             images with typical features

          -  patient with unresectable primary hepatocellular carcinoma

          -  Child-Pugh Class A or B, score ≤ 7

          -  ECOG score 0-2

          -  Expected survival time not less than 12 weeks

          -  At least one tumor nodule with one uni-dimension of ≥ 1 cm

          -  Peripheral platelet of or more than 50×10(9)/L

          -  Peripheral hemoglobin of or more than 85g/L

          -  Peripheral albumen of or more than 28g/L

          -  Total bilirubin ≤3.0mg/dl

          -  ALT and AST ≤ 5.0 x the upper limit of normal

          -  Serum amylase ≤ 1.5x the upper limit of normal

          -  Serum creatinine ≤ 1.5x upper limit of normal

          -  PT-INR&lt;2.3 or PT prolong no more than 4s of normal

        Exclusion Criteria:

          -  Congestive heart failure &gt; NYHA class 2

          -  History of active coronary disease( except myocardial infarction more than 6 months
             ago)

          -  Receive anti-arrhythmia treatment(except β-receptor blocker,calcium channel blocker
             and digoxin)

          -  uncontrollable hypertension

          -  Active clinically serious infections (&gt; 2 NCI-CTC Version 3.0)

          -  History of HIV infection

          -  Inclined to hemorrhage or active hemorrhage with 1 month

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in this study

          -  Pregnant or breast-feeding.Women of childbearing potential must have a negative
             pregnancy test performed within 7 days prior to enrolling in this portion of the study

          -  Known or suspected allergy to any agent given in association with this trial

          -  Concomitant anti-cancer therapy (except immunotherapy and Chinese traditional
             treatment)

          -  Surgical operation within 4 weeks prior to enrolling in this portion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zheng-Gang Ren, Ph.D</last_name>
    <phone>0086-021-64041990</phone>
    <phone_ext>2149</phone_ext>
    <email>ren.zhenggang@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lan Zhang, Master</last_name>
    <phone>0086-021-64041990</phone>
    <phone_ext>2171</phone_ext>
    <email>zhang.lan@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liver Cancer Institute</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng-Gang Ren, Ph.D</last_name>
      <phone>0086-021-64041990</phone>
      <phone_ext>2137</phone_ext>
      <email>ren.zhenggang@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Lan Zhang, Master</last_name>
      <phone>0086-021-64041990</phone>
      <phone_ext>2171</phone_ext>
      <email>zhang.lan@zs-hospital.sh.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zheng-Gang Ren, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jubo Zhang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2010</study_first_submitted>
  <study_first_submitted_qc>December 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2010</study_first_posted>
  <last_update_submitted>April 13, 2011</last_update_submitted>
  <last_update_submitted_qc>April 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ren Zhenggang/Professor Sun Huichuan/Professor</name_title>
    <organization>Shanghai Zhongshan Hospital,China</organization>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Zoledronic Acid</keyword>
  <keyword>toxic reaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

